Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product

MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.

Read More

Exact Sciences Completes 68,000 Cologuard Tests During the Third Quarter

Revenues exceed $28 million, grow 123 percent year-over-year, 33 percent sequentially

MADISON, Wis., Oct. 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $28.1 million during the third quarter ended Sept. 30, 2016, an increase of 123 percent from $12.6 millionin the third quarter of 2015.  The company completed approximately 68,000 Cologuard tests during the quarter, an increase of approximately 100 percent from the same quarter of 2015. Since the launch of Cologuard and through the end of the third quarter of 2016, nearly 50,000 providers have ordered the test.

Read More

Exact Sciences Announces Inclusion of Cologuard® in HEDIS Quality Measures

Cologuard offers opportunity for health plans, systems & providers to improve quality ratings

MADISON, Wis., Oct. 3, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS.

Read More